|COVID–19 NEWS||Vaccination programme for construction sector to begin July 1 | India reports 51,667 new COVID cases over past 24 hours | PIKAS well-received with applications coming from over 2,000 companies with 301,050 workers -- Azmin | COVID: Sabah records two workplace clusters today | COVID: Four new clusters declared in Sarawak ||
NEW DELHI, May 13 -- India's Drugs Controller General (DCGI) has approved Phase II/III clinical trials of the COVAXIN vaccine against coronavirus for children aged 2-18.
The trials will be conducted in 525 healthy volunteers, the ministry of health announced on Thursday.
"The DCGI, after careful examination, has accepted the recommendation of Subject Expert Committee and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID vaccine) in the age group 2 to 18 years, to its manufacturer Bharat Biotech Ltd ... The trial will be conducted in 525 healthy volunteers," Sputnik news quoting the ministry said in a press release.
The vaccine will be administered by intramuscular injections in two doses on day 0 and day 28, it added.
Bernama is the trusted source of reliable real-time comprehensive and accurate news for both the public and media practitioners. Our news is published at www.bernama.com ; BERNAMA TV on: Astro Channel 502, unifi TV Channel 631, MYTV Channel 121 IFLIX; and Bernama Radio broadcasting locally on FM93.9 in Klang Valley, Johor (FM107.5), Kota Kinabalu (FM107.9) and Kuching (FM100.9).
Follow us on social media :
Facebook : @bernamaofficial, @bernamatv, @bernamaradio
Twitter : @bernama.com, @BernamaTV, @bernamaradio
Instagram : @bernamaofficial, @bernamatvofficial, @bernamaradioofficial
TikTok : @bernamaofficial